JPWO2021097360A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021097360A5
JPWO2021097360A5 JP2022528305A JP2022528305A JPWO2021097360A5 JP WO2021097360 A5 JPWO2021097360 A5 JP WO2021097360A5 JP 2022528305 A JP2022528305 A JP 2022528305A JP 2022528305 A JP2022528305 A JP 2022528305A JP WO2021097360 A5 JPWO2021097360 A5 JP WO2021097360A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022528305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502968A5 (https=
JP7722990B2 (ja
JP2023502968A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/060596 external-priority patent/WO2021097360A1/en
Publication of JP2023502968A publication Critical patent/JP2023502968A/ja
Publication of JP2023502968A5 publication Critical patent/JP2023502968A5/ja
Publication of JPWO2021097360A5 publication Critical patent/JPWO2021097360A5/ja
Priority to JP2025104401A priority Critical patent/JP2025134876A/ja
Application granted granted Critical
Publication of JP7722990B2 publication Critical patent/JP7722990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022528305A 2019-11-15 2020-11-13 アミロイド沈着物を標的化するための修飾免疫グロブリン Active JP7722990B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025104401A JP2025134876A (ja) 2019-11-15 2025-06-20 アミロイド沈着物を標的化するための修飾免疫グロブリン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962936002P 2019-11-15 2019-11-15
US62/936,002 2019-11-15
US202063074912P 2020-09-04 2020-09-04
US63/074,912 2020-09-04
PCT/US2020/060596 WO2021097360A1 (en) 2019-11-15 2020-11-13 Modified immunoglobulins for targeting amyloid deposits

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025104401A Division JP2025134876A (ja) 2019-11-15 2025-06-20 アミロイド沈着物を標的化するための修飾免疫グロブリン

Publications (4)

Publication Number Publication Date
JP2023502968A JP2023502968A (ja) 2023-01-26
JP2023502968A5 JP2023502968A5 (https=) 2023-11-20
JPWO2021097360A5 true JPWO2021097360A5 (https=) 2023-11-20
JP7722990B2 JP7722990B2 (ja) 2025-08-13

Family

ID=75912899

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022528305A Active JP7722990B2 (ja) 2019-11-15 2020-11-13 アミロイド沈着物を標的化するための修飾免疫グロブリン
JP2025104401A Pending JP2025134876A (ja) 2019-11-15 2025-06-20 アミロイド沈着物を標的化するための修飾免疫グロブリン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025104401A Pending JP2025134876A (ja) 2019-11-15 2025-06-20 アミロイド沈着物を標的化するための修飾免疫グロブリン

Country Status (11)

Country Link
US (5) US20220411489A1 (https=)
EP (1) EP4058479A4 (https=)
JP (2) JP7722990B2 (https=)
KR (1) KR20220113950A (https=)
CN (1) CN115298214A (https=)
AU (1) AU2020385183A1 (https=)
BR (1) BR112022009273A2 (https=)
CA (1) CA3158206A1 (https=)
IL (1) IL292903B2 (https=)
MX (1) MX2022005850A (https=)
WO (1) WO2021097360A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4058479A4 (en) 2019-11-15 2024-02-28 University of Tennessee Research Foundation MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS
WO2022120378A1 (en) * 2020-12-04 2022-06-09 University Of Tennessee Research Foundation Method for diagnosing amyloid diseases
JP2024519488A (ja) * 2021-05-05 2024-05-14 ユニバーシティ オブ テネシー リサーチ ファウンデーション アミロイド疾患を治療するためのペプチド-fc融合体
JP2024521082A (ja) * 2021-05-18 2024-05-28 ユニバーシティ オブ テネシー リサーチ ファウンデーション アミロイド障害を処置するための抗体-ペプチド融合タンパク質
AU2022346750A1 (en) * 2021-09-14 2024-04-11 Caelum Biosciences, Inc. Method of treating multiple myeloma
EP4430071A4 (en) * 2021-11-12 2026-01-14 Adrx Inc ANTIBODIES BINDING TO THE TRANSTHYRETIN (TTR) MONOMER
US20250298033A1 (en) * 2022-05-11 2025-09-25 Alexion Pharmaceuticals, Inc. High sensitivity biotinylated peptide binding elisa assay
US20260070962A1 (en) * 2022-09-02 2026-03-12 University Of Tennessee Research Foundation Chimeric antigen receptors for removal of amyloid
AU2024339036A1 (en) 2023-09-07 2026-03-12 University Of Tennessee Research Foundation Method for diagnosing amyloid diseases
WO2025212955A1 (en) 2024-04-05 2025-10-09 University Of Tennessee Research Foundation Method for diagnosing amyloid diseases
WO2026055521A1 (en) * 2024-09-06 2026-03-12 University Of Tennessee Research Foundation Antibody-peptide fusion proteins for treating amyloid disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
EP0733070A1 (en) * 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
DE69942274D1 (de) * 1998-05-21 2010-06-02 Univ Tennessee Res Foundation Methoden zur amyloidentfernung mit anti-amyloid-antikörper
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
KR101017732B1 (ko) * 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-cd74 항체 및 그 이용방법
JP5137400B2 (ja) 2003-06-30 2013-02-06 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
DE602006008460D1 (de) 2005-06-17 2009-09-24 Ca Nat Research Council NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON
EP2125893A2 (en) * 2007-01-23 2009-12-02 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
DK2237803T3 (en) * 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
WO2011119608A1 (en) 2010-03-26 2011-09-29 University Of Tennessee Research Foundation Peptides that specifically target amyloid deposits
US20140079691A1 (en) 2012-09-20 2014-03-20 Anaptysbio, Inc. Thermostable antibody framework regions
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
KR20240095466A (ko) 2017-01-30 2024-06-25 내션얼 리서치 카운슬 오브 캐나다 혈액-뇌 장벽을 관통이동하는 화합물 및 이의 용도
RU2746325C1 (ru) * 2017-06-29 2021-04-12 Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк Химерные антитела для лечения заболеваний, характеризующихся отложением амилоида
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
IL279399B1 (en) 2018-06-14 2026-04-01 Bioatla Llc Multispecific antibody templates
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
EP4058479A4 (en) 2019-11-15 2024-02-28 University of Tennessee Research Foundation MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS
JP2024521082A (ja) 2021-05-18 2024-05-28 ユニバーシティ オブ テネシー リサーチ ファウンデーション アミロイド障害を処置するための抗体-ペプチド融合タンパク質

Similar Documents

Publication Publication Date Title
JP2025134876A5 (https=)
JP7019198B2 (ja) 補体関連疾患の予防及び治療のためのc5抗体及び方法
US12215167B2 (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
AU2009245354C1 (en) Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
KR102757960B1 (ko) 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
AU2013211939B2 (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US20050288491A1 (en) Super-humanized antibodies against respiratory syncytial virus
JP2012515746A (ja) 抗cd160モノクローナル抗体及びその使用
HRP20110599T1 (hr) Antitijela protiv toksina clostridium difficile i njihove primjene
KR20190025938A (ko) Anti-met 항체 및 그 용도
JP2005528914A5 (https=)
US20240336674A1 (en) Anti-sema3a antibodies and their uses for treating eye or ocular diseases
JPWO2021097360A5 (https=)
JP2022521305A (ja) 抗pd-l1抗体及びその使用
KR20260030123A (ko) 혈액 뇌 장벽을 통과하여 그라눌린을 전달하기 위한 화합물
US20230287090A1 (en) USE OF SARS-CoV-2 RECEPTOR BINDING MOTIF (RBM)-REACTIVE MONOCLONAL ANTIBODIES TO TREAT COVID-19
CN116234577A (zh) 用于治疗和预防covid-19的sars-cov-2抗体
CN112480259A (zh) 抗tnfr2抗体及其用途
JPWO2022111425A5 (https=)
WO2025086564A1 (zh) 抗人vsig4的抗体及其医药用途
JP2025539937A (ja) 抗papp-a抗体及びその使用方法
TW202330601A (zh) TfR抗原結合蛋白及其用途
AU2018271836B2 (en) Anti-dengue virus antibody, pharmaceutical composition comprising the same, and uses thereof
WO2025241702A1 (zh) 靶向hla-g的抗体或其抗原结合片段及其应用
JP2025078038A (ja) SARS-CoV-2変異株特異的認識抗体